Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.9 USD | -0.50% | +2.51% | +34.82% |
15/03 | North American Morning Briefing : Inflation -2- | DJ |
14/03 | Wells Fargo Upgrades NeuroPace to Overweight From Equalweight, Raises Price Target to $20 From $16 | MT |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 245.1 | 37.11 | 271 | 399.2 | - | - |
Enterprise Value (EV) 1 | 275.7 | 83.41 | 346 | 422.8 | 443.6 | 457.9 |
P/E ratio | -4.65 x | -0.78 x | -8.12 x | -11.9 x | -14.4 x | -27.5 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 5.42 x | 0.82 x | 4.14 x | 5.31 x | 4.51 x | 3.71 x |
EV / Revenue | 6.1 x | 1.83 x | 5.29 x | 5.62 x | 5.02 x | 4.26 x |
EV / EBITDA | -11.8 x | -2.59 x | -19.8 x | -20.6 x | -25 x | -40 x |
EV / FCF | -11 x | -2.23 x | -17.4 x | -19.7 x | -25.8 x | -32.7 x |
FCF Yield | -9.05% | -44.9% | -5.74% | -5.08% | -3.88% | -3.06% |
Price to Book | 3.35 x | 1.07 x | 13.9 x | 49.5 x | -43.7 x | -18 x |
Nbr of stocks (in thousands) | 24,314 | 24,903 | 26,284 | 28,720 | - | - |
Reference price 2 | 10.08 | 1.490 | 10.31 | 13.90 | 13.90 | 13.90 |
Announcement Date | 10/03/22 | 02/03/23 | 05/03/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | 41.14 | 45.18 | 45.52 | 65.42 | 75.21 | 88.44 | 107.5 |
EBITDA 1 | - | -23.44 | -32.18 | -17.44 | -20.5 | -17.77 | -11.46 |
EBIT 1 | - | -23.74 | -40.79 | -27.17 | -27.04 | -22.68 | -12.75 |
Operating Margin | - | -52.54% | -89.62% | -41.54% | -35.96% | -25.65% | -11.86% |
Earnings before Tax (EBT) 1 | - | -36.08 | -47.08 | -32.96 | -32.1 | -25.22 | -11.67 |
Net income 1 | -24.28 | -36.08 | -47.08 | -32.96 | -32.22 | -27.58 | -15.26 |
Net margin | -59.02% | -79.85% | -103.43% | -50.38% | -42.84% | -31.19% | -14.2% |
EPS 2 | -45.31 | -2.170 | -1.910 | -1.270 | -1.169 | -0.9654 | -0.5062 |
Free Cash Flow 1 | - | -24.96 | -37.47 | -19.87 | -21.5 | -17.2 | -14 |
FCF margin | - | -55.24% | -82.32% | -30.38% | -28.59% | -19.45% | -13.03% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 24/03/21 | 10/03/22 | 02/03/23 | 05/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 10.34 | 11 | 11.37 | 10.2 | 11.16 | 12.79 | 14.47 | 16.51 | 16.43 | 18.01 | 17.3 | 18.19 | 18.78 | 20.7 | 19 |
EBITDA 1 | -6.168 | -8.936 | -8.194 | -8.298 | -7.957 | -7.729 | -6.146 | -5.151 | -3.493 | -2.654 | -5.733 | -5 | -4.667 | -4.167 | -7 |
EBIT 1 | -6.243 | -9.015 | -9.762 | -10.97 | -10.2 | -9.859 | -8.319 | -7.854 | -5.95 | -5.051 | -7.915 | -7.188 | -6.54 | -5.499 | -7 |
Operating Margin | -60.38% | -81.98% | -85.83% | -107.59% | -91.41% | -77.09% | -57.48% | -47.57% | -36.22% | -28.04% | -45.74% | -39.51% | -34.82% | -26.57% | -36.84% |
Earnings before Tax (EBT) 1 | -8.083 | -10.69 | -11.46 | -12.69 | -11.78 | -11.15 | -10.38 | -9.124 | -7.257 | -6.2 | -8.9 | -8.325 | -7.85 | -7.025 | -8 |
Net income 1 | -8.083 | -10.69 | -11.46 | -12.69 | -11.78 | -11.15 | -10.38 | -9.124 | -7.257 | -6.2 | -8.896 | -8.445 | -7.769 | -7.124 | -8 |
Net margin | -78.18% | -97.24% | -100.76% | -124.41% | -105.63% | -87.15% | -71.69% | -55.26% | -44.18% | -34.42% | -51.41% | -46.42% | -41.37% | -34.42% | -42.11% |
EPS 2 | -0.3400 | -0.4400 | -0.4700 | -0.5200 | -0.4800 | -0.4500 | -0.4100 | -0.3600 | -0.2800 | -0.2300 | -0.3232 | -0.3035 | -0.2841 | -0.2586 | -0.3300 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 10/11/21 | 10/03/22 | 12/05/22 | 11/08/22 | 08/11/22 | 02/03/23 | 04/05/23 | 08/08/23 | 06/11/23 | 05/03/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | 30.7 | 46.3 | 75 | 23.6 | 44.4 | 58.7 |
Net Cash position 1 | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | -1.308 x | -1.439 x | -4.3 x | -1.153 x | -2.499 x | -5.128 x |
Free Cash Flow 1 | - | -25 | -37.5 | -19.9 | -21.5 | -17.2 | -14 |
ROE (net income / shareholders' equity) | - | -107% | -87% | -119% | -232% | -629% | - |
ROA (Net income/ Total Assets) | - | -38.1% | -38% | -29.7% | -34.5% | -38% | -28.8% |
Assets 1 | - | 94.76 | 123.8 | 110.9 | 93.52 | 72.55 | 53 |
Book Value Per Share 2 | - | 3.010 | 1.390 | 0.7400 | 0.2800 | -0.3200 | -0.7700 |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | 0.38 | 0.6 | 0.17 | 2 | 1.45 | 1.6 |
Capex / Sales | - | 0.85% | 1.32% | 0.26% | 2.66% | 1.64% | 1.49% |
Announcement Date | 24/03/21 | 10/03/22 | 02/03/23 | 05/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+34.82% | 401M | |
+7.62% | 219B | |
+6.70% | 183B | |
+11.94% | 132B | |
+24.60% | 106B | |
-2.66% | 62.09B | |
+4.81% | 50.88B | |
+11.55% | 50.8B | |
-1.09% | 40.64B | |
+26.82% | 31.59B |
- Stock Market
- Equities
- NPCE Stock
- Financials NeuroPace, Inc.